The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: A systematic review

Annals of Nuclear Medicine

Volumn 26, Issue 6, 2012, Pages 451-461

  Treglia, Giorgio ^a   Giovannini, Elisabetta ^b   Di Franco, Davide ^a   Calcagni, Maria Lucia ^a   Rufini, Vittoria ^a   Picchio, Maria ^c   Giordano, Alessandro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Carbon 11; Choline; Fluorine 18; Oncology; PET CT; Positron emission tomography

Indexed keywords

CARBON 11; CHOLINE; FLUORODEOXYGLUCOSE F 18;

BRAIN TUMOR; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; EMBASE; HEAD AND NECK TUMOR; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MEDLINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SCORING SYSTEM; STEREOTACTIC BIOPSY; SYSTEMATIC REVIEW; TUMOR RECURRENCE;

CARBON RADIOISOTOPES; CHOLINE; FLUORINE RADIOISOTOPES; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84864706647     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0602-7     Document Type: Review

References (62)

1. Chen K, Chen X. Positron emission tomography imaging of cancer biology: current status and future prospects. Semin Oncol. 2011;38:70-86.
2. Chiti A, Picchio M. The rising PET: the increasing use of choline PET/CT in prostate cancer. Eur J Nucl Med Mol Imagin. 2011;38:53-4.
3. Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging. 2010;37:2188-93.
4. Nanni C, Rubello D, Fanti S. Could choline PET play a role in malignancies other than prostate cancer? Eur J Nucl Med Mol Imaging. 2008;35:216-8. (Pubitemid 350234156)
5. Picchio M, Giovannini E, Messa C. The role of PET/computed tomography scan in the management of prostate cancer. Curr Opin Urol. 2011;21:230-6.
6. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. (18)F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15:45-55.
7. Zeisel SH, Blusztajn JK. Choline and human nutrition. Annu Rev Nutr. 1994;14:269-96. (Pubitemid 24261839)
8. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999;12:413-39. (Pubitemid 30016999)
9. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011;11:835-48.
10. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42(12): 1805-14. (Pubitemid 34016349)
11. Hara T, Kosaka N, Shinoura N, Kondo T. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med. 1997;38:842-7. (Pubitemid 27251970)
12. Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T, et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med. 2001;28:1664-70. (Pubitemid 33036109)
13. Utriainen M, Komu M, Vuorinen V, Lehikoinen P, Sonninen P, Kurki T, et al. Evaluation of brain tumor metabolism with [11C]choline PET and 1H-MRS. J Neurooncol. 2003;62:329-38. (Pubitemid 36591970)
14. Hara T, Kondo T, Hara T, Kosaka N. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg. 2003;99:474-9. (Pubitemid 37040406)
15. Tian M, Zhang H, Oriuchi N, Higuchi T, Endo K. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging. 2004;31: 1064-72. (Pubitemid 39050172)
16. Tian M, Zhang H, Higuchi T, Oriuchi N, Endo K. Oncological diagnosis using (11)C-choline-positron emission tomography in comparison with 2-deoxy-2-[(18)F] fluoro-D-glucose-positron emission tomography. Mol Imaging Biol. 2004;6:172-9. (Pubitemid 38771980)
17. Kwee SA, Ko JP, Jiang CS, Watters MR, Coel MN. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology. 2007;244:557-65. (Pubitemid 47080889)
18. Huang Z, Zuo C, Guan Y, Zhang Z, Liu P, Xue F, et al. Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours. Nucl Med Commun. 2008;29:354-8. (Pubitemid 351644384)
19. Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, et al. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol. 2008;29:1176-82. (Pubitemid 351954890)
20. Giovacchini G, Fallanca F, Landoni C, Gianolli L, Picozzi P, Attuati L, et al. C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience. Clin Nucl Med. 2009;34:7-10.
21. Takenaka S, Shinoda J, Asano Y, Aki T, Miwa K, Ito T, et al. Metabolic assessment of monofocal acute inflammatory demyelination using MR spectroscopy and (11)C-methionine-, (11)Ccholine-, and (18)F-fluorodeoxyglucose-PET. B. Brain Tumor Pathol. 2011;28:229-38.
22. Rottenburger C, Hentschel M, Kelly T, Trippel M, Brink I, Reithmeier T, et al. Comparison of C-11 methionine and C-11 choline for PET imaging of brain metastases: a prospective pilot study. Clin Nucl Med. 2011;36:639-42.
23. Tan H, Chen L, Guan Y, Lin X. Comparison of MRI, F-18 FDG, and 11C-choline PET/CT for their potentials in differentiating brain tumor recurrence from brain tumor necrosis following radiotherapy. Clin Nucl Med. 2011;36:978-81.
24. Roelcke U, Bruehlmeier M, Hefti M, Hundsberger T, Nitzsche EU. F-18 choline PET does not detect increased metabolism in F-18 fluoroethyltyrosine- negative low-grade gliomas. Clin Nucl Med. 2012;37:e1-3.
25. Li FM, Nie Q, Wang RM, Chang SM, Zhao WR, Zhu Q, et al. (11)C-CHO PET in optimization of target volume delineation and treatment regimens in postoperative radiotherapy for brain gliomas. Nucl Med Biol 2012;39:437-42.
26. Ninomiya H, Oriuchi N, Kahn N, Higuchi T, Endo K, Takahashi K, et al. Diagnosis of tumor in the nasal cavity and paranasal sinuses with [11C]choline PET: comparative study with 2-[18F]fluoro-2-deoxy-D-glucose (FDG) PET. Ann Nucl Med. 2004;18:29-34. (Pubitemid 38478406)
27. Khan N, Oriuchi N, Ninomiya H, Higuchi T, Kamada H, Endo K. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET. Ann Nucl Med. 2004;18:409-17. (Pubitemid 39265062)
28. Ito K, Yokoyama J, Kubota K, Morooka M, Shiibashi M, Matsuda H. 18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intraarterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. Eur J Nucl Med Mol Imaging. 2010;37:1318-27.
29. Ito K, Yokoyama J, Kubota K, Morooka M. Comparison of 18F-FDG and 11C-choline PET/CT for detecting recurrences in patients with nonsquamous cell head and neck malignancies. Nucl Med Commun. 2010;31:931-7.
30. Wu HB, Wang QS, Wang MF, Zhen X, Zhou WL, Li HS. Preliminary study of 11C-choline PET/CT for T staging of locally advanced nasopharyngeal carcinoma: comparison with 18F-FDG PET/CT. J Nucl Med. 2011;52:341-6.
31. Kobori O, Kirihara Y, Kosaka N, Hara T. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer. 1999;86:1638-48. (Pubitemid 29513031)
32. Jager PL, Que TH, Vaalburg W, Pruim J, Elsinga P, Plukker JT. Carbon-11 choline or FDG-PET for staging of oesophageal cancer? Eur J Nucl Med. 2001;28:1845-9.
33. Liu Q, Peng ZM, Liu QW, Yao SZ, Zhang L, Meng L, et al. The role of 11C-choline positron emission tomography-computed tomography and videomediastinoscopy in the evaluation of diseases of middle mediastinum. Chin Med J. 2006;119:634-9. (Pubitemid 43796843)
34. Peng ZM, Liu Q, Liu QW, Yao SZ, Meng L, Liu Q, et al. The value of dual time point 11C-choline PET-CT in differentiating malignant from benign lesion of mediastinum. Zhonghua Yi Xue Za Zhi. 2007;87:3317-20. (Pubitemid 351356133)
35. Hara T, Inagaki K, Kosaka N, Morita T. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11Ccholine PET. J Nucl Med. 2000;41:1507-13.
36. Pieterman RM, Que TH, Elsinga PH, Pruim J, van Putten JW, Willemsen AT, et al. Comparison of (11)C-choline and (18)FFDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med. 2002;43:167-72. (Pubitemid 34151038)
37. Khan N, Oriuchi N, Zhang H, Higuchi T, Tian M, Inoue T, et al. A comparative study of 11C-choline PET and [18F]fluorodeoxyglucose PET in the evaluation of lung cancer. Nucl Med Commun. 2003;24:359-66.
38. Hara T, Kosaka N, Suzuki T, Kudo K, Niino H. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest. 2003;124:893-901. (Pubitemid 37123306)
39. Wang T, Sun YE, Yao SL, Yu CH, Yin DY, Tian JH. Value of carbon-11 choline positron emission tomography in patients with pulmonary abnormalities. Zhonghua Wai Ke Za Zhi. 2006;44: 405-8.
40. Wang T, Sun YE, Chu XY, Yao SL, Yang B, Tian JH, et al. Positron emission tomography with special tracers in pulmonary abnormalities. Zhonghua Wai Ke Za Zhi. 2010;48:99-102.
41. Balogova S, Huchet V, Kerrou K, Nataf V, Gutman F, Antoine M, et al. Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nucl Med Commun. 2010;31:389-97.
42. Peng Z, Liu Q, Li M, Han M, Yao S, Liu Q. Comparison of (11)C-choline PET/CT and enhanced CT in the evaluation of patients with pulmonary abnormalities and locoregional lymph node involvement in lung cancer. Clin Lung Cancer. 2011. doi: 10.1016/j.cllc.2011.09.005.
43. Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, et al. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F] FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006;33(11): 1285-9. (Pubitemid 44630783)
44. Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A, et al. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med. 2008;49:1245-8.
45. Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010;51:1699-706.
46. van den Esschert JW, Bieze M, Beuers UH, van Gulik TM, Bennink RJ. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18F-fluorocholine PET/CT. Eur J Nucl Med Mol Imaging. 2011;38:436-40.
47. Wu HB, Wang QS, Li BY, Li HS, Zhou WL, Wang QY. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med. 2011;36:1092-7.
48. de Jong IJ, Pruim J, Elsinga PH, Jongen MM, Mensink HJ, Vaalburg W. Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging. 2002;29:1283-8. (Pubitemid 44392207)
49. Picchio M, Treiber U, Beer AJ, Metz S, Bössner P, van Randenborgh H, et al. Value of 11C-choline PET and contrastenhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med. 2006;47:938-44. (Pubitemid 46939945)
50. Gofrit ON, Mishani E, Orevi M, Klein M, Freedman N, Pode D, et al. Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol. 2006;176:940-4. (Pubitemid 44142556)
51. Maurer T, Souvatzoglou M, Kübler H, Opercan K, Schmidt S, Herrmann K, et al. Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol. 2012;61:1031-38.
52. Golan S, Sopov V, Baniel J, Groshar D. Comparison of 11Ccholine with 18F-FDG in positron emission tomography/computerized tomography for staging urothelial carcinoma: a prospective study. J Urol. 2011;186:436-41.
53. Torizuka T, Kanno T, Futatsubashi M, Okada H, Yoshikawa E, Nakamura F, et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med. 2003;44:1051-6. (Pubitemid 39663379)
54. Sofue K, Tateishi U, Sawada M, Maeda T, Terauchi T, Kano D, et al. Role of carbon-11 choline PET/CT in the management of uterine carcinoma: initial experience. Ann Nucl Med. 2009;23: 235-43.
55. Contractor KB, Kenny LM, Stebbing J, Al-Nahhas A, Palmieri C, Sinnett D, et al. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res. 2009;15:5503-10.
56. Kenny LM, Contractor KB, Hinz R, Stebbing J, Palmieri C, Jiang J, et al. Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab. Clin Cancer Res. 2010;16:4236-45.
57. Contractor KB, Kenny LM, Stebbing J, Challapalli A, Al-Nahhas A, Palmieri C, et al. Biological basis of [11C]choline-positron emission tomography in patients with breast cancer: comparison with [18F]fluorothymidine positron emission tomography. Nucl Med Commun. 2011;32:997-1004.
58. Zhang H, Tian M, Oriuchi N, Higuchi T, Watanabe H, Aoki J, et al. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET. Nucl Med Commun. 2003;24:273-9.
59. Tian M, Zhang H, Endo K. Comparison of cell proliferation, protein, and glucose metabolism in musculoskeletal tumors in a PET study. J Biomed Biotechnol. 2011;2011:807929.
60. Yanagawa T, Watanabe H, Inoue T, Ahmed AR, Tomiyoshi K, Shinozaki T, et al. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. J Comput Assist Tomogr. 2003;27:175-82. (Pubitemid 37047214)
61. Tateishi U, Yamaguchi U, Maeda T, Seki K, Terauchi T, Kawai A, et al. Staging performance of carbon-11 choline positron emission tomography/computed tomography in patients with bone and soft tissue sarcoma: comparison with conventional imaging. Cancer Sci. 2006;97:1125-8. (Pubitemid 44322564)
62. Nanni C, Zamagni E, Cavo M, Rubello D, Tacchetti P, Pettinato C, et al. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol. 2007;5:68.